Detalhe da pesquisa
1.
Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
BMC Cancer;
22(1): 228, 2022 Mar 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35236333
2.
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.
Pharm Res;
39(4): 669-676, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35352280
3.
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
Pharm Res;
39(10): 2507-2514, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35978149
4.
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Eur J Clin Pharmacol;
77(4): 441-464, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33165648
5.
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.
Eur J Clin Pharmacol;
76(8): 1075-1082, 2020 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32430518
6.
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
Ther Drug Monit;
41(5): 561-567, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31568233
7.
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
Eur J Clin Pharmacol;
75(9): 1309-1318, 2019 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31175385
8.
Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
BMC Cancer;
18(1): 1200, 2018 Dec 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30509247
9.
Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis.
BMC Nephrol;
18(1): 378, 2017 12 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29287588
10.
Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Eur J Clin Pharmacol;
77(4): 465, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33320282
11.
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.
Cancer Chemother Pharmacol;
91(6): 447-456, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36947208
12.
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Clin Cancer Res;
28(17): 3709-3719, 2022 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35699623
13.
Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review.
BMJ Open;
12(1): e053308, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34980620
14.
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Clin Pharmacol Ther;
111(2): 477-484, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34674222
15.
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Biomed Pharmacother;
153: 113393, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35834987
16.
The Right Dose: From Phase I to Clinical Practice.
Am Soc Clin Oncol Educ Book;
41: 92-106, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34010057
17.
Precision Dosing of Targeted Therapies Is Ready for Prime Time.
Clin Cancer Res;
27(24): 6644-6652, 2021 12 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34548319
18.
Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Clin Pharmacol Ther;
109(2): 394-402, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32686074
19.
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Cancers (Basel);
13(24)2021 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34944899
20.
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Clin Pharmacokinet;
59(12): 1501-1520, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33029704